- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02648425
Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine
Phase I Study to Evaluate the Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-Fluorouracil or Cisplatin and Capecitabine
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is an open-label, Phase I, dose escalation study of ASLAN001 given in combination with Regimen A or Regimen B, in patients with metastatic solid tumors, eligible to receive the cisplatin/5-fluorouracil or cisplatin/capecitabine regimen.
Dose of ASLAN001 starts from 400mg BID; then, dose escalation to 500mg BID or dose de-escalation to 300mg BID will depend on DLTs observed in cohort.
Regimen A: Depends on preferred medical practice, Cohort 1A will receive ASLAN001 400 mg BID in combination with cisplatin 80 mg/m2 IV infusion and 5 fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks; or will receive ASLAN001 400 mg BID in combination with Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks.
Regimen B: Cohort 1B will receive ASLAN001 400 mg BID in combination with cisplatin 80 mg/m2 IV infusion and oral capecitabine 1,000 mg/m2 BID for 14 days every 3 weeks.
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Male or female patients 20 years of age or older at the time written informed consent is obtained.
Regimen A: Patients with metastatic solid tumors eligible for treatment with cisplatin and 5-fluorouracil. The standard dose and schedule of cisplatin and 5-fluorouracil will be according to the preference of investigators and institutions.
Regimen B: Patients with metastatic solid tumors eligible for treatment with cisplatin in combination with capecitabine.
- Patients with a partial gastrectomy may be allowed to participate in the study as long as they can take oral medications and meet all other inclusion/exclusion criteria.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate organ and hematological function as evidenced by the following laboratory studies within 14 days prior to enrolment:
Hematological function, as follows:
- Absolute neutrophil count ≥ 1.5 x 109/L.
- Platelet count ≥ 100 x 109/L.
- Hemoglobin ≥ 9 g/dL.
Coagulation function, as follows:
- Partial thromboplastin time or activated partial thromboplastin time ≤ 1.5 x upper limit of normal (ULN) per institutional laboratory normal range.
- International normalized ratio ≤ 1.5.
Renal function, as follows:
• Creatinine clearance ≥ 50 mL/min as calculated by Cockcroft-Gault formula.
Hepatic function, as follows:
- Total bilirubin ≤ 1.5 x ULN.
- AST and ALT ≤ 2.5 x ULN (≤ 5 x ULN if liver metastases are present).
Exclusion Criteria:
- Patients with persistent gastric outlet obstruction, complete dysphagia or feeding jejunostomy.
- Patients receiving proton pump inhibitors or H2 antagonists for established, symptomatic gastro duodenal ulceration or gastroesophageal reflux disease.
- Patients with unresolved toxicities of grade 2 or more from prior anti-cancer therapies.
- Untreated or symptomatic central nervous system metastases. Patients with a history of brain metastases are eligible if definitive therapy has been administered (surgery and/or radiation therapy), there is no planned treatment for brain metastases, and the patient is clinically stable and is off corticosteroids for at least 2 weeks prior to enrolment.
- Major surgical procedures within 28 days prior to enrolment.
- Clinically significant cardiovascular diseases that are symptomatic or uncontrolled.
- Known positive test for human immunodeficiency virus, hepatitis C, or hepatitis B surface antigen.
- Pregnant or breast-feeding females.
- Patients who have hearing impairment, due to the potential for ototoxicity of cisplatin.
- Any history or presence of clinically significant cardiovascular, respiratory, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic or psychiatric disease or any other condition which in the opinion of the Investigator could jeopardize the safety of the patient or the validity of the study results
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Regimen A / Amended Regimen A
Regimen A: Cisplatin + 5-fluorouracil ASLAN001 daily in combination with: Cisplatin 80 mg/m2 IV infusion for 1 day and 5-fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks for up to 6 cycles. Or Amended Regimen A: Cisplatin + 5-fluorouracil + leucovorin ASLAN001 daily in combination with: Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks for up to 6 cycles. |
ASLAN001 400mg BID daily; ASLAN001 500mg BID daily; or ASLAN001 300mg BID daily
Autres noms:
Cisplatin 80 mg/m2 IV infusion and 5-fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks; Or Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks. |
Expérimental: Regimen B
Regimen B: Cisplatin + capecitabine ASLAN001 daily in combination with: Cisplatin 60-80 mg/m2 IV infusion on Day 1 and capecitabine 1,000 mg/m2 orally BID for 14 days every 3 weeks for up to 6 cycles. |
ASLAN001 400mg BID daily; ASLAN001 500mg BID daily; or ASLAN001 300mg BID daily
Autres noms:
Cisplatin 80 mg/m2 IV infusion and capecitabine 1,000 mg/m2 orally BID for 14 days every 3 weeks
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Safety and Tolerability of ASALN001
Délai: First 2 cycles
|
Safety and tolerability as evaluated with: DLTs (in first 2 cycles); Maximum tolerated dose (MTD) of ASLAN001 in combination with cisplatin/capecitabine or cisplatin/5-FU will be determined. |
First 2 cycles
|
Safety and Tolerability of ASALN001
Délai: Baseline to post-dose
|
Safety and tolerability as evaluated with: Adverse events. |
Baseline to post-dose
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Preliminary assessment of the efficacy
Délai: Along the study duration
|
•To provide a preliminary assessment of the efficacy of ASLAN001 when given in combination in Regimen A or Regimen B as measured by the objective response rate (ORR).
|
Along the study duration
|
Pharmacokinetics profile (AUC) of ASLAN001
Délai: Along the study duration
|
To evaluate the pharmacokinetics of ASLAN001, when given in combination with Regimen A or Regimen B. Pharmacokinetic parameters including, but not limited to area under the plasma concentration-time curve (AUC) from 0 to 6 hours (AUC0-6).
|
Along the study duration
|
Pharmacokinetics profile (Cmax) of ASLAN001
Délai: Along the study duration
|
To evaluate the pharmacokinetics of ASLAN001, when given in combination with Regimen A or Regimen B. Pharmacokinetic parameters including, but not limited to maximum plasma concentration (Cmax).
|
Along the study duration
|
Pharmacokinetics profile (Cmin) of ASLAN001
Délai: Along the study duration
|
To evaluate the pharmacokinetics of ASLAN001, when given in combination with Regimen A or Regimen B. Pharmacokinetic parameters including, but not limited to minimum (trough) plasma concentration (Cmin).
|
Along the study duration
|
Pharmacokinetics profile (RacAUC0-6) of ASLAN001
Délai: Pharmacokinetic measurements will be from Cycle 1 Day 1 to Cycle 3 Day 1 (each cycle is 28 days for Amended Regimen A, and 21 days for Regimen A and B.
|
To evaluate the pharmacokinetics of ASLAN001, when given in combination with Regimen A or Regimen B. Pharmacokinetic parameters including, but not limited to accumulation ratio for AUC (RacAUC0-6).
|
Pharmacokinetic measurements will be from Cycle 1 Day 1 to Cycle 3 Day 1 (each cycle is 28 days for Amended Regimen A, and 21 days for Regimen A and B.
|
Pharmacokinetics profile (Tmax) of ASLAN001
Délai: Along the study duration
|
To evaluate the pharmacokinetics of ASLAN001, when given in combination with
|
Along the study duration
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chaise d'étude: ASLAN Pharma, ASLAN Pharmaceuticals
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Effets physiologiques des médicaments
- Mécanismes moléculaires de l'action pharmacologique
- Antimétabolites, Antinéoplasique
- Antimétabolites
- Agents antinéoplasiques
- Agents immunosuppresseurs
- Facteurs immunologiques
- Agents protecteurs
- Micronutriments
- Vitamines
- Antidotes
- Complexe de vitamine B
- Cisplatine
- Fluorouracile
- Capécitabine
- Leucovorine
Autres numéros d'identification d'étude
- ASLAN001-002
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Tumeur solide
-
AstraZenecaRecrutementAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian CancerEspagne, États-Unis, Belgique, Royaume-Uni, France, Hongrie, Canada, Corée, République de, Australie
-
Shattuck Labs, Inc.Actif, ne recrute pasMélanome | Carcinome à cellules rénales | Lymphome de Hodgkin | Adénocarcinome gastrique | Cancer du poumon non à petites cellules | Carcinome épidermoïde de la tête et du cou | Lymphome diffus à grandes cellules B | Carcinome urothélial | Adénocarcinome de la jonction gastro-oesophagienne | Carcinome... et d'autres conditionsÉtats-Unis, Canada, Belgique, Espagne
Essais cliniques sur ASLAN001
-
ASLAN PharmaceuticalsComplétéCholangiocarcinomeTaïwan, Corée, République de, Singapour
-
ASLAN PharmaceuticalsComplétéCancer de l'estomacEstonie, Hong Kong, Corée, République de, Lituanie, Malaisie, Singapour, Taïwan, Thaïlande
-
ASLAN PharmaceuticalsComplétéTumeurs solides avancées ou métastatiques | Cancer des voies biliaires avancé ou métastatiqueJapon
-
National Cancer Centre, SingaporeNational Medical Research Council (NMRC), Singapore; ASLAN PharmaceuticalsActif, ne recrute pas
-
ASLAN PharmaceuticalsSyneos Health; bioRASI, LLC; CMIC Co, Ltd. JapanComplétéCancer des voies biliairesÉtats-Unis, Australie, Chine, Hong Kong, Hongrie, Japon, Corée, République de, Pologne, Singapour, Espagne, Taïwan
-
ASLAN PharmaceuticalsComplétéCancer du sein métastatiqueAustralie, Hong Kong, Corée, République de, Nouvelle-Zélande, Philippines, Singapour, Taïwan
-
National University Hospital, SingaporeInconnue
-
ASLAN PharmaceuticalsRésiliéCancer des voies biliairesTaïwan, Corée, République de, Singapour